TrialJCO precision oncology2025

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (

Tejas Patil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.